|
Early Access Programs - The Definitive Test for Guiding Pharma's Commercialization Strategy, Upcoming Webinar Hosted by Xtalks
Thursday, November 14, 2024
In this free webinar, learn about the fundamentals of early access, including history, definitions, nomenclature, country archetypes, strategic considerations, operational elements and data capture. The featured speakers will discuss why running early access programs is vital for launch and the importance of getting the launch right. Attendees will learn about pharma commercialization approach and how early access programs fit into this. The speakers will share critical success factors and potential pitfalls to avoid when running early access programs. Attendees will also learn about using early access programs as an exit strategy.
TORONTO, Nov. 6, 2024 /PRNewswire-PRWeb/ -- Commercializing a new medicine is a complex undertaking, with various elements that need to be planned for and understood prior to launch. The success of a launch can vary greatly between assets depending on how a company manages this. The majority of launches have their longer-term fate determined in the first six months of their commercial life.
Providing patients with access to these medicines can have a dramatic positive effect on a patient's quality of life, and in some cases, can extend or even save a patient's life.After that period of time, it is very difficult to make up the ground lost before. Early access programs not only help to create early engagement with the medical community enabling more successful launches but also provide an opportunity for the pharmaceutical company to build pre-launch experience in various markets to help them to make informed decisions about their organizational structure (commercial strategy (including price)).
This enables companies to identify which markets to prioritize or maybe decide not to launch in at all. Essentially early access programs allow pharma to 'test the waters' to understand real-world demand and facilitate decision making based on factual information, with the added benefits of being able to understand patient pathways, engage with payers, develop prescriber relationships, collect outcomes data, generate revenue and demonstrate demand / willingness to pay for their product.
From a patient perspective, early access programs provide access to promising medicines before launch (if they are not participating in the clinical trial), which would have otherwise not been available to them for as long as three to four years, following the first global approval of the medicine (e.g. US Food and Drug Administration (FDA) or European Medicines Agency (EMA)). Providing patients with access to these medicines can have a dramatic positive effect on a patient's quality of life, and in some cases, can extend or even save a patient's life.
During the webinar, participants will get expert perspectives on how early access programs are a critical element to any commercial planning process. They will discuss best practices on how considering early access programs during clinical phases II and III can help achieve success and help define strategy and objectives, maximize benefit for patients/company and strengthen launch trajectory/commercial proposition.
Register for this webinar today to discover how early access programs can shape successful pharmaceutical commercialization.
Join Paul Stanton, Senior Director, Global Strategy, Early Access, Inceptua Group; and Sebastian Stachowiak, CEO, ICE BIOPHARMA, for the live webinar on Wednesday, November 27, 2024, at 10am EST (4pm CET/EU-Central).
For more information, or to register for this event, visit Early Access Programs - The Definitive Test for Guiding Pharma's Commercialization Strategy.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com
View original content to download multimedia:https://www.prweb.com/releases/early-access-programs--the-definitive-test-for-guiding-pharmas-commercialization-strategy-upcoming-webinar-hosted-by-xtalks-302297104.html
SOURCE Xtalks
|
|
|
|
|
|
 |
VIAVI Highlights Test Solutions for AI Infrastructure Development, Manufacturing and Deployment at OFC 2025 | Mar 28, 2025
|
|
Orium Launches Composable Accelerator for Shopify | Mar 28, 2025
|
|
Oracle Helps Customers Boost Employee Engagement with Strategic Communications and Internal Events | Mar 28, 2025
|
|
ThreatQuotient positioned as a Leader in the SPARK Matrix(TM): Digital Threat Intelligence Management, 2025 by QKS Group | Mar 28, 2025
|
|
Madame Rachida Dati, French Minister of Culture, has granted official recognition to thierry Ehrmann's Abode of Chaos as a 'total work of art', the global headquarters of Artprice by Artmarket. | Mar 28, 2025
|
|
Datacenter Dynamics Makes History with LoneStar - Becoming the World's First Magazine to Reach the Moon | Mar 28, 2025
|
|
Oracle Named a Leader in Configure, Price, Quote by Independent Research Firm | Mar 28, 2025
|
|
Nosto reports 323% growth of Personalized Search after 2024 Gartner MQ inclusion | Mar 28, 2025
|
|
Western Union forms strategic partnership with HCLTech to transition to an AI led platform operating model | Mar 28, 2025
|
|
Wealthbox Expands to Canada with In-Country Data Hosting | Mar 28, 2025
|
|
|
|
